BioTech Pharma
TB-500 research vial

2D Molecular Structure

TB-500 2D molecular structure for compound 62707662
CID
62707662
Standard InChIKey
ADKDNDYYIZUVCZ-ZQNQAVPYSA-N
FDA UNII
QHK6Z47GTG
Residue Count
7 AA
Structural Modifications
  • N-terminal acetyl
  • Free C-terminal acid
  • Thymosin β4 (17-23) fragment — not full-length protein
regenerative Research

TB-500

Also known as: Thymosin β4 (17-23) acetylated fragment, Ac-LKKTETQ, N-Acetyl-Tβ4(17-23)

N-acetylated heptapeptide corresponding to the thymosin β4 (17-23) actin-binding region, the identity registered for the research code "TB-500."
CAS Number
885340-08-9
Purity
Batch-specific
Form
Lyophilized powder
Enquiry Sizes
Research vial • Bulk / custom fill (quote required)
Peptide Sequence7 residues
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

Compliance Notice: All products supplied by BioTech Pharma are intended strictly for laboratory research and development use only. They are not intended for human or veterinary use, diagnosis, treatment, or consumption of any kind. By submitting an enquiry, the requester confirms they are a qualified researcher or institution and accepts full responsibility for compliant handling and use.

Configure Your Request

Documentation requests are reviewed against the records available for the applicable lot. Availability, methods, and values must be confirmed for the specific enquiry and are not promised in advance.

Form supplied: Lyophilized powder. Your selections are carried into the quote request automatically.

Overview

The research code "TB-500" is registered in the FDA Global Substance Registration System (UNII QHK6Z47GTG) as the N-terminally acetylated heptapeptide N-Acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln, corresponding to residues 17-23 of thymosin β4. This segment overlaps the LKKTETQ actin-binding motif of the parent 43-residue protein and is the defined molecular entity BioTech Pharma supplies under this catalog name.

The full-length thymosin β4 protein is a distinct, larger molecule, and the "TB-500" label has historically been applied loosely to both the intact protein and this fragment. To keep chemical identity unambiguous, this product is fixed to the acetylated 17-23 fragment as characterized in the analytical literature; lot-specific analytical documentation may be available and should be confirmed for the applicable material.

In preclinical and in-vitro work, the LKKTETQ region of thymosin β4 has been studied in the published literature for its role in G-actin sequestration and cytoskeletal dynamics. These model observations are exploratory, do not establish clinical efficacy, and should be distinguished from any established pharmacology; the peptide is offered strictly as a research reagent and is not a drug or a product for human or veterinary use.

Research Applications

  • Actin sequestration and cytoskeletal dynamics assays
  • Thymosin β4 fragment structure-activity studies
  • Cell-migration and in-vitro cell-model research
  • Peptide identity and analytical characterization work

Frequently Asked Questions

Scientific References

Analytical Data

Lot-specific documentation may be available for the applicable material and must be confirmed per enquiry. Where available, it may include:

  • HPLC purity result
  • LC-MS identity confirmation
  • Appearance
  • Net content

Request the records you need with your quote and we will confirm availability for your batch.

Procurement Details

Availability, lead time, salt / content basis, and cold-chain requirements depend on the specific lot and quantity, so we confirm them per enquiry rather than publishing fixed figures. Request confirmation for your requirements with your quote and our team will respond with details for the applicable batch.

Storage & Handling

Lyophilized powder: store desiccated at −20 °C, protected from light and moisture. Reconstitute immediately before use; prepared aqueous solutions should be kept cold (2–8 °C) and used within an empirically determined stability window for the applicable material.

Related Compounds